Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: The Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS).
(2011) In Atherosclerosis 215. p.440-445- Abstract
- OBJECTIVES: To examine whether the decrease in IMT progression rate in the carotid bulb induced by metoprolol CR/XL treatment (25mg once daily) observed in the β-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS) was accompanied by an effect on carotid plaque echogenicity. METHODS: Gray scale median (GSM) in carotid plaques, used as a score of echogenicity, was measured at baseline and after 36 months in those 341 subjects (aged 49-69 years) with an asymptomatic moderate- to large-sized carotid plaque present at baseline and at follow-up. Participants were in a factorial design assigned to treatment with metoprolol CR/XL (25mg once daily), fluvastatin (40mg once daily) or corresponding placebo. RESULTS: After 36 months plaques... (More)
- OBJECTIVES: To examine whether the decrease in IMT progression rate in the carotid bulb induced by metoprolol CR/XL treatment (25mg once daily) observed in the β-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS) was accompanied by an effect on carotid plaque echogenicity. METHODS: Gray scale median (GSM) in carotid plaques, used as a score of echogenicity, was measured at baseline and after 36 months in those 341 subjects (aged 49-69 years) with an asymptomatic moderate- to large-sized carotid plaque present at baseline and at follow-up. Participants were in a factorial design assigned to treatment with metoprolol CR/XL (25mg once daily), fluvastatin (40mg once daily) or corresponding placebo. RESULTS: After 36 months plaques were more echogenic in participants treated compared to those not treated with metoprolol CR/XL (57.3±16.8 versus 51.8±20.0, p=0.006). GSM had increased more from baseline in the metoprolol CR/XL treated subjects (25±15 versus 18±20, p<0.001), and plaques that had become more echolucent were less frequent in the metoprolol CR/XL treated subjects (3.6% versus 17.0%, p<0.001). CONCLUSIONS: Long-term treatment with low dose metoprolol CR/XL in clinically healthy subjects with moderate-sized carotid plaques was associated with increase in plaque echogenicity, suggesting a potential beneficial effect of the β-blocker treatment on plaque stability. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1831918
- author
- Östling, Gerd LU ; Goncalves, Isabel LU ; Wikstrand, John ; Berglund, Göran LU ; Nilsson, Jan LU and Hedblad, Bo LU
- organization
-
- EXODIAB: Excellence of Diabetes Research in Sweden
- EpiHealth: Epidemiology for Health
- Internal Medicine - Epidemiology (research group)
- Cardiovascular Research - Immunity and Atherosclerosis (research group)
- Cardiovascular Research - Translational Studies (research group)
- Cardiovascular Research - Epidemiology (research group)
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Atherosclerosis
- volume
- 215
- pages
- 440 - 445
- publisher
- Elsevier
- external identifiers
-
- wos:000288940000027
- pmid:21315352
- scopus:79953062298
- pmid:21315352
- ISSN
- 1879-1484
- DOI
- 10.1016/j.atherosclerosis.2010.12.031
- language
- English
- LU publication?
- yes
- id
- 76e34369-21cd-4c03-87c0-985db3fb856e (old id 1831918)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21315352?dopt=Abstract
- date added to LUP
- 2016-04-01 10:47:16
- date last changed
- 2022-04-20 06:14:12
@article{76e34369-21cd-4c03-87c0-985db3fb856e, abstract = {{OBJECTIVES: To examine whether the decrease in IMT progression rate in the carotid bulb induced by metoprolol CR/XL treatment (25mg once daily) observed in the β-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS) was accompanied by an effect on carotid plaque echogenicity. METHODS: Gray scale median (GSM) in carotid plaques, used as a score of echogenicity, was measured at baseline and after 36 months in those 341 subjects (aged 49-69 years) with an asymptomatic moderate- to large-sized carotid plaque present at baseline and at follow-up. Participants were in a factorial design assigned to treatment with metoprolol CR/XL (25mg once daily), fluvastatin (40mg once daily) or corresponding placebo. RESULTS: After 36 months plaques were more echogenic in participants treated compared to those not treated with metoprolol CR/XL (57.3±16.8 versus 51.8±20.0, p=0.006). GSM had increased more from baseline in the metoprolol CR/XL treated subjects (25±15 versus 18±20, p<0.001), and plaques that had become more echolucent were less frequent in the metoprolol CR/XL treated subjects (3.6% versus 17.0%, p<0.001). CONCLUSIONS: Long-term treatment with low dose metoprolol CR/XL in clinically healthy subjects with moderate-sized carotid plaques was associated with increase in plaque echogenicity, suggesting a potential beneficial effect of the β-blocker treatment on plaque stability.}}, author = {{Östling, Gerd and Goncalves, Isabel and Wikstrand, John and Berglund, Göran and Nilsson, Jan and Hedblad, Bo}}, issn = {{1879-1484}}, language = {{eng}}, pages = {{440--445}}, publisher = {{Elsevier}}, series = {{Atherosclerosis}}, title = {{Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: The Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS).}}, url = {{https://lup.lub.lu.se/search/files/2136931/1858592.pdf}}, doi = {{10.1016/j.atherosclerosis.2010.12.031}}, volume = {{215}}, year = {{2011}}, }